ASTRAZENECA PLC
NASDAQ: AZN
=
66.81
0.00
0.00%
1 Day
-
Open
66.54
-
Previous Close
66.81
-
Volume (Avg)
2.40M (5.80M)
-
Day's Range
66.20-66.92
-
52Wk Range
53.63-71.70
-
Market Cap.
206.03B
-
Dividend Rate (Yield)
1.90 (2.84%)
-
Beta
-
-
Shares Outstanding
-
-
P/E Ratio (EPS)
492.77 (-)
Top Stories
-
Enhertu significantly delayed breast cancer progression in trial, AstraZeneca says
MarketWatch 1 day ago -
UK first to approve Omicron COVID shot with Moderna nod
Reuters -
Inovio Pharmaceuticals (INO) Q2 2022 Earnings Call Transcript
The Motley Fool -
Covid-19 vaccines in pregnancy not linked to miscarriage or stillbirth
New Scientist -
Major changes to healthcare coming as Manchin-Schumer bill heads to Biden’s desk
Washington Examiner 3 days ago -
Misrepresentation of Germany’s Data on Unverified COVID-19 Vaccine Side Effects
FactCheck.org -
More than a half billion doses of COVID vaccine made in Baltimore dumped, congressional panel finds
Baltimore Sun -
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Benzinga -
AstraZeneca's (AZN) Lynparza sNDA Gets FDA Priority Tag
Zacks.com -
What to Know About Evusheld If You’re at Risk for Severe COVID-19
Self [Non-Video] -
You May Not Know About Evusheld For COVID, But Health Experts Want You To
Health Digest -
Trump-tied conservatives are 15 states away from an unprecedented rewrite of the Constitution
Business Insider -
Here’s How the COVID Vaccine May Temporarily Change Your Period
Self [Non-Video] -
AstraZeneca PLC (LON:AZN) Given Average Recommendation of “Buy” by Brokerages
Defense World -
Mitsubishi UFJ Kokusai Asset Management Co. Ltd. Takes Position in AstraZeneca PLC (NASDAQ:AZN)
Defense World 2 days ago -
AstraZeneca-Merck's Prostate Cancer Drug Under FDA Priority Review For Expanded Use
YAHOO!Finance -
AstraZeneca PLC AZNCF Stock Quote
Morningstar%2c Inc. -
AstraZeneca PLC 2022 Q2 - Results - Earnings Call Presentation
Seeking Alpha
